Inhibition of Mycoplasma pneumoniae growth by FDA-approved anticancer and antiviral nucleoside and nucleobase analogs

Table 2 Inhibition of tritium labelled natural nucleoside and nucleobase uptake and metabolism by selected analogs*

	[³H]-dT		[³H]-Ura		[³H]-Hx		[³H]-Gua		[³H]-Ade
	Total uptake	Incorporation	Total uptake	Incorporation	Total uptake	Incorporation	Total uptake	Incorporation	Total uptake	Incorporation
None	7.6±0.5	97.5±0.5	0.20±0.003	40±5	0.050± 0.001	62±7	0.9±0.05	56±3	0.62±0.1	44±1
Dipyridamole	7.2±1.1	97.0±1.3	0.20±0.003	38±6	0.008± 0.001	44±3	0.09±0.002	56±6	0.67±0.1	47±1
6-TG	7.9±0.6	97.4±0.7	0.21±0.003	39±8	0.005 ± 0.0004	43±6	0.080±0.002	67±3	0.66±0.1	46±3
TFT	18.2±0.6	97.4±0.5	0.11±0.002	27±0.2	0.011± 0.001	67±1	0.19±0.02	85±4	0.43±0.01	48±2
5FdU	14.7±0.2	96.0±0.5	0.087±0.003	19±7	0.006± 0.001	76±4	0.16±0.03	87±3	0.36±0.1	42±2
dFdC	5.2±0.4	96.7±1.1	0.12±0.001	26±6	0.009±0.0002	67±7	0.10±0.02	90±6	0.41±0.08	39±8

*Total uptake: percentage of radioactivity recovered in the cells divided by total radioactivity added to the growth medium.
Incorporation: percentage of radioactivity in the acid insoluble fraction divided by total radioactivity recovered in the cells.

ISSN: 1471-2180